Table 1.
All patients n = 149 (%) | No GLT N = 83 |
GLT N = 66 |
P-value | |
---|---|---|---|---|
Median age (years) | 68 | |||
Mean age (SD) | 67.76 (10.56) | 65.03 (11.97) | .142 | |
ECOG | .319 | |||
ECOG performance status ≤1 | 114 (77) | |||
ECOG 0 | 59 (39.6) | 32(38.6) | 27(40.9) | |
ECOG 1 | 55 (36.9) | 27(32.5) | 28(42.4) | |
ECOG 2 | 23 (15.4) | 14(16.9) | 9(13.6) | |
ECOG 3 | 7 (4.7) | 6 (7.2) | 1(1.5) | |
Unknown | 5 (3.4) | 4(4.8) | 1 (1.5) | |
Sex | ||||
Male | 71 (47.7) | |||
Female | 78 (52.3) | |||
Race/ethnicity | .796 | |||
Non- Hispanic black | 40 (26.8) | 21(25.3) | 19(28.8) | |
Non-Hispanic white | 44 (29.5) | 22(26.5) | 22(33.3) | |
Hispanic | 34 (22.8) | 21(25.3) | 13(19.7) | |
Asian | 19 (12.8) | 12(14.5) | 7(10.6) | |
Other ethnicity | 12 (8.1) | 7(8.4) | 5(7.6) | |
Ashkenazi Jewish | 3 (2.0) | |||
Family h/o cancer | 93 (62.4) | 44(53) | 49(74.2) | .013 |
Family h/o DDR pathway cancers | 49 (32.9) | 22(26.5) | 27(40.9) | .092 |
Prostate | 5 (3.4) | |||
Pancreatic | 14 (9.4) | |||
Breast | 17 (11.4) | |||
Endometrial | 2 (1.3) | |||
Ovarian | 3 (2.0) | |||
Colorectal | 13 (8.7) | |||
FDR or SDR with pancreatic cancer | 22 (14.8) | |||
Personal history of non-pancreatic cancer | 25 (16.8) | |||
Breast | 4 (1.6) | |||
Prostate | 3 (1.2) | |||
Ovarian | 1 (0.4) | |||
Endometrial | 2 (0.8) | |||
Stomach | 1 (0.4) | |||
Lung | 2 (0.8) | |||
Lymphoma/leukemia | 1 (0.4) | |||
Thyroid | 1 (0.4) | |||
Renal | 1 (0.4) | |||
Bladder | 2 (0.8) | |||
Prostate and lung | 1 (0.4) | |||
Skin | 2 (0.8) | |||
Testicular | 1 (0.4) | |||
Gallbladder | 1 (0.4) | |||
Vulvar | 1 (0.4) | |||
Tonsillar | 1 (0.4) | |||
Comorbidities: | ||||
Diabetes mellitus | 55 (37.0) | |||
Hypertension | 93 (62.4) | |||
Hyperlipidemia | 64 (43.0) | |||
CAD | 29 (19.5) | |||
Thyroid disorder | 12 (8.1) | |||
HIV | 4 (2.7) |
Abbreviations: CAD, coronary artery disease; DDR, DNA damage repair; ECOG, Eastern Cooperative Oncology Group; FDR, first degree relative; h/o, History of; SDR, second degree relative; GLT: germline testing.